Analysts Set AxoGen, Inc. (NASDAQ:AXGN) Price Target at $13.80

Shares of AxoGen, Inc. (NASDAQ:AXGN) have been assigned an average rating of “Buy” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on the stock in the last year is $13.80.

Several equities analysts have recently commented on the stock. Raymond James started coverage on shares of AxoGen in a research note on Monday, July 1st. They set an “outperform” rating and a $13.00 price objective for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price objective on shares of AxoGen in a report on Thursday, June 20th. JMP Securities lifted their price objective on AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Friday, August 9th. Finally, StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a report on Friday, August 9th.

Institutional Trading of AxoGen

Several large investors have recently bought and sold shares of AXGN. Koss Olinger Consulting LLC bought a new stake in shares of AxoGen during the 2nd quarter valued at $75,000. Lazard Asset Management LLC lifted its position in AxoGen by 30.1% during the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after acquiring an additional 2,671 shares during the period. Acadian Asset Management LLC bought a new stake in AxoGen during the second quarter worth about $125,000. BNP Paribas Financial Markets grew its holdings in AxoGen by 8.6% in the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock worth $168,000 after purchasing an additional 1,651 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of AxoGen by 8.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock valued at $240,000 after purchasing an additional 2,204 shares in the last quarter. 80.29% of the stock is owned by institutional investors.

AxoGen Price Performance

AXGN opened at $13.02 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.51 and a quick ratio of 2.32. The stock’s 50 day simple moving average is $10.11 and its 200 day simple moving average is $8.37. The firm has a market cap of $569.04 million, a price-to-earnings ratio of -26.04 and a beta of 1.12. AxoGen has a 1 year low of $3.45 and a 1 year high of $13.35.

AxoGen (NASDAQ:AXGN) last issued its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. The firm had revenue of $47.91 million for the quarter, compared to analysts’ expectations of $43.27 million. As a group, analysts predict that AxoGen will post -0.33 earnings per share for the current year.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.